VERITAC-2
The trial that got the first PROTAC approved, with benefit only in tumours with ESR1 mutations.
PFS 5.0 vs 2.1 months (HR 0.57) in ESR1-mutant; no benefit in overall population. Approved Q2 2026 for ESR1-mutant disease.
- Median 5 vs 2.1 months with Vepdegestrant compared with Fulvestrant; about 2.9 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 43 percent lower chance of the event at any given time (hazard ratio 0.57, likely range 0.42 to 0.77).
- Median 3.7 vs 3.6 months with Vepdegestrant compared with Fulvestrant; about 0.1 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 17 percent lower chance of the event at any given time (hazard ratio 0.83, likely range 0.68 to 1.02).
- The likely range for the hazard ratio crosses 1, so the difference could be due to chance.
- Not significant.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: ER+/HER2- advanced breast cancer after CDK4/6 and endocrine therapy: vepdegestrant vs fulvestrant. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (HER2); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
624 participants enrolled.
Not significant
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival, ESR1-mutant (BICR)primary | Vepdegestrant | 136 | 5 months | 0.57 (0.42–0.77) | <0.001 | link |
| Fulvestrant | 134 | 2.1 months | ||||
| Progression-free survival, ITTprimary | Vepdegestrant | 313 | 3.7 months | 0.83 (0.68–1.02) | — | link |
| Fulvestrant | 311 | 3.6 months |
Pages like this
not linked directly; found by shared links- PersonFrançois-Clément Bidard
Shares Fulvestrant, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- TrialpostMONARCH
Shares Fulvestrant, HR-positive / HER2-negative breast cancer.
- TermOral SERD
Shares Fulvestrant, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- TriallidERA
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- TrialSOLAR-1
Shares Fulvestrant, HR-positive / HER2-negative breast cancer.
- TrialINAVO120
Shares Fulvestrant, HR-positive / HER2-negative breast cancer.
- TrialCAPItello-291
Shares Fulvestrant, HR-positive / HER2-negative breast cancer.
- CompanyArvinas
Shares Vepdegestrant, HR-positive / HER2-negative breast cancer.